Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track EDSA with free AI briefings, catalyst countdowns, and dilution alerts.

EDSA · Edesa Biotech, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$10.3M Cash on Hand
12.1mo Cash Runway
Follow EDSA by email Get an email when EDSA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EDSA, unsubscribe in one click. Privacy

📣 What EDSA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SOC plus 15mg/kg EB05 IV COVID-19 Phase 2/3 · NCT04401475 Terminated
Cohort A: vilobelimab Acute Respiratory Distress Syndrome (ARDS) Phase 2 · NCT06701682 Recruiting
Cohort B: paridiprubart Acute Respiratory Distress Syndrome (ARDS) Phase 2 · NCT06703073 Recruiting
Cohort C: bevacizumab Acute Respiratory Distress Syndrome (ARDS) Phase 2 · NCT06703073 Recruiting
EB01 Cream 0.2% Allergic Contact Dermatitis Phase 2 · NCT03680131 Completed
EB01 Cream 1.0% Allergic Contact Dermatitis Phase 2 · NCT03680131 Completed
EB01 Cream 2.0% Allergic Contact Dermatitis Phase 2 · NCT03680131 Completed
EB06 Non-Segmental Vitiligo (NSV) Phase 2 · NCT07889492 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EDSA holds $10.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 12.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 47 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EDSA files for a raise →

👥 Who Owns EDSA

Insiders 22.2% Other 5%+ holders 17.6% Institutions 60.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
Sirenia Capital Management LP Institution (13G, 5%+) 3,339,767 34.64% 2026-09-30
Pardeep Nijhawan
Chief Executive Officer, Director, 10% o
Insider 1,472,700 15.28% 2026-11-04
StemPoint Capital LP Institution (13G, 5%+) 1,407,181 14.60% 2026-09-30
Velan Capital Investment Management LP Institution (13G, 5%+) 1,356,455 14.07% 2026-08-21
Millennium Management LLC 5%+ holder (13G) 1,178,577 12.22% 2026-09-30
Adage Capital Management, L.P. Institution (13G, 5%+) 1,100,000 11.41% 2026-09-30
Stonepine Capital Management, LLC Institution (13G, 5%+) 953,739 9.89% 2026-08-20
Boxer Capital Management, LLC Institution (13G, 5%+) 937,363 9.72% 2026-09-30
Integrated Core Strategies (US) LLC 5%+ holder (13G) 520,685 5.40% 2026-06-11
Michael J Brooks
President
Insider 291,479 3.02% 2026-05-27
Peter J. Weiler
Chief Financial Officer
Insider 129,609 1.34% 2026-05-27
Patrick Marshall
Director
Insider 72,131 0.75% 2026-05-27

Share count 9,641,031 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full EDSA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EDSA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.